Jonathan Langley

Jonathan has been employed at senior level in the pharmaceutical industry for more than 20 years, principally in areas of Clinical Development and Medical Affairs. Jonathan also has extensive expertise in the field of Rare Diseases, particularly in respiratory indications including Pulmonary Arterial Hypertension (PAH) where he has more than 15 years’ experience at national and global levels. Prior to joining Galapagos, Jonathan served as the Global Medical Affairs Lead for the Pulmonary Hypertension portfolio at Glaxo Smith Kline (GSK) LTD (NL & UK).

While at GSK, he led the late stage PAH clinical development program which included running the successful pivotal Phase III AMBITION clinical trial that demonstrated the importance of use of Ambrisentan and Tadalafil in combination therapy as a first-line treatment for PAH. Prior to this, he has held senior positions at Actelion Pharmaceuticals (UK) and at the Pfizer Pharmaceuticals Group Ltd (London & Kent, UK., and in Tokyo, JP). He has widely published in PAH in leading journals, and brings extensive knowledge of, and experience in, the Pulmonary Hypertension market.